Introduction {#s1}
============

Exposure to particulate matter (PM) air pollution is associated with significant morbidity and mortality and is one of the top preventable causes of death in the world ([@bib13]). The World Health Organization estimates that exposure to air pollution is responsible for 4.2 million premature deaths worldwide every year ([@bib23]). Air pollution has been identified as a leading cause of global disease burden, and as the fifth mortality risk factor particularly in low- and middle-income countries ([@bib4]). The majority of PM-associated morbidity and mortality is due to cardiopulmonary diseases including asthma, chronic obstructive lung disease, lung cancer, congestive heart failure and ischemic/thrombotic cardiovascular disease (myocardial infarction, ischemic stroke) ([@bib4]; [@bib9]).

We have previously shown that lung macrophages are required for PM-induced lung inflammation and consequently acute thrombotic events ([@bib17]; [@bib3]; [@bib20]). PM induces the release of pro-inflammatory cytokines including interleukin-6 (IL-6), which is required for the PM-induced prothrombotic state and resultant acceleration of vascular thrombosis ([@bib17]; [@bib3]). Furthermore, we found that PM affects mitochondrial function in lung macrophages characterized by increased oxygen consumption rate and generation of reactive oxygen species (ROS), which are both required for PM-induced IL-6 production ([@bib20]).

Despite significant improvement in our understanding about the mechanisms by which PM induces pro-inflammatory cytokines such as IL-6, the mechanisms that regulate PM-induced lung inflammation are not completely understood. To better understand these mechanisms, we performed RNA-sequencing in macrophages following PM exposure. Here, we demonstrate that PM regulates the expression of genes that have not been previously reported. One of the top genes induced by PM was *Irg1* (Immune-responsive Gene 1) or *Acod1* (Aconitate decarboxylase 1), which encodes a mitochondrial enzyme that produces itaconate from the Tricarboxylic Acid (TCA) cycle metabolite cis-aconitate ([@bib21]; [@bib14]). Itaconate has been reported to be produced in macrophages following LPS stimulation and to have anti-inflammatory effects ([@bib12]; [@bib15]). We confirmed that PM induces both mRNA and protein expression of Acod1 in macrophages, and increases intracellular and media levels of itaconate. Our metabolic analysis showed that itaconate inhibits mitochondrial complex II (succinate dehydrogenase) and that Acod1 is an important regulator of cellular respiration following PM exposure. Treatment of macrophages with a cell-permeable itaconate derivative, 4-octyl itaconate (OI) attenuated PM- and LPS-induced cytokine production. *Acod1^-/-^* cells, which lack endogenous itaconate production, exhibited exaggerated IL-1β production following LPS exposure; however, no effect on PM-induced inflammation was observed. As recently described, OI induced NRF2 protein and expression of its target genes such as *Nqo1* and *Hmox1* ([@bib15]); however, we found that NRF2 was not required for the anti-inflammatory effects of OI. Furthermore, using *Acod1^-/-^* cells, we found that endogenous itaconate production is not required for NRF2 protein or its target gene expression following treatment with either PM or LPS. These results suggest that recently reported anti-inflammatory and NRF2-inducing effects of exogenous itaconate (OI) may not represent the effects of endogenously-produced itaconate and therefore OI should not be used as a surrogate for Acod1 and endogenous itaconate. Collectively, our results suggest that stimulus and location of itaconate production play major roles in governing the effect of itaconate on inflammation in macrophages. Furthermore, in contrast to recent studies, we suggest that NRF2 is not a major regulator of the anti-inflammatory effects of itaconate.

Results {#s2}
=======

Particulate matter induces aconitate decarboxylase 1 (*Acod1*) and production of itaconate in macrophages {#s2-1}
---------------------------------------------------------------------------------------------------------

Previous studies that evaluated the effect of PM on macrophages have evaluated a limited number of regulated genes, primarily focusing on pro-inflammatory cytokines. To gain a non-biased understanding of the mechanisms by which PM induces lung inflammation, we treated BMDMs from C57BL/6 mice with PM or vehicle control for 24 hours and performed RNA-Seq to analyze PM-induced changes in the transcriptome. Differentially expressed gene (DEG) analysis revealed 370 unique genes significantly regulated by PM. Gene ontology analysis of RNA-seq data showed upregulation of pathways relating to inflammatory responses, metabolism, and cytokine stimulation ([Figure 1A](#fig1){ref-type="fig"}). The most highly upregulated gene induced by PM exposure was *Acod1* ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Other highly upregulated genes included proinflammatory cytokine genes such as *Tnfa, Il1b* as well as *Nqo1,* a transcriptional target of Nuclear factor (erythroid-derived 2)-like 2 (NRF2) ([Figure 1B](#fig1){ref-type="fig"}).

![Aconitate Decarboxylase 1 (Acod1) is highly upregulated by particulate matter in macrophages.\
(**A**) We performed RNA-seq in BMDMs treated with either PM (20 μg/cm^2^) or vehicle control for 24 hours. Gene ontology analysis highlight the pathways involved with PM treatment. (**B**) Volcano plot of RNA-seq data representing differentially expressed genes in BMDMs treated with PM or PBS (vehicle control) for 24 hours. *Acod1* (red point) is one of the most highly differentially expressed gene. In addition, we found induction of NRF2 target genes (i.e. *Nqo1, Gclm*; turquoise points) and inflammatory genes (i.e. *Tnf, Il1b*; orange points) following PM treatment. Black data points represent other significant genes, at FC \> 2, and FDR adjusted p\<0.05. (**C**) qPCR analysis of *Acod1* in BMDMs treated with PM for 4, 8 or 24 hours. Data are represented as fold change. Significance was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**D**) Western blot of ACOD1 protein at 0, 4, 8, 24 and 48 hours of PM treatment. (**E**) Intracellular itaconate concentration in BMDMs treated with PM for 24 hours, as measured by mass spectrometry. (**F**) Extracellular itaconate in media in BMDMs treated with PM for 24 hours, as measured using mass spectrometry. Significance was determined using two-tailed unpaired student's t-test, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.\
Figure 1---source data 1.Differential expression analysis results of PM treated BMDMs compared with Control BMDMs.](elife-54877-fig1){#fig1}

*Acod1* encodes a mitochondrial enzyme, which catalyzes the conversion of cis-aconitate to itaconate, a mitochondrial metabolite that has recently been shown to regulate inflammatory responses ([@bib14]). To confirm that PM upregulates mRNA and protein expression of Acod1, we first treated BMDMs with PM for 4, 8 or 24 hours, and then assessed the expression of *Acod1* through qPCR and western blot over time. PM induced *Acod1* gene expression as early as 4 hours after treatment, peaking at 8 hours ([Figure 1C](#fig1){ref-type="fig"}). Western blot analysis showed expression of ACOD1 protein was delayed compared to mRNA expression and was detectable beginning 24 hours after PM treatment ([Figure 1D](#fig1){ref-type="fig"}). To determine whether Acod1 protein induction was associated with increased cellular levels of its metabolic product, we measured intracellular levels of itaconate in BMDMs 24 hours after treatment with PM using capillary electrophoresis--mass spectrometry (CE-MS) (Human Metabolome Technologies, Boston, MA). We found that PM caused a significant increase in intracellular itaconate levels ([Figure 1E](#fig1){ref-type="fig"}), correlating with the upregulation of ACOD1. Furthermore, we detected increased concentrations of itaconate via mass spectrometry in the medium of macrophages treated with PM, indicating that itaconate is released from cells ([Figure 1F](#fig1){ref-type="fig"}). Collectively, these findings demonstrate that PM causes a time-dependent expression of ACOD1 and production of itaconate, prompting us to further study whether itaconate plays a role in the regulation of PM-induced inflammation.

Itaconate decreases mitochondrial oxygen consumption by inhibiting succinate dehydrogenase/complex II in macrophages {#s2-2}
--------------------------------------------------------------------------------------------------------------------

Since itaconate has been shown to be a weak inhibitor of complex II, succinate dehydrogenase (SDH) ([@bib5]; [@bib12]), we hypothesized that PM exposure may regulate mitochondrial respiration in macrophages through induction of Acod1 and production of itaconate.

We first confirmed that itaconate inhibits SDH in BMDMs using the Seahorse XF Plasma Membrane Permeabilizer to assess the effect of itaconate on individual mitochondrial respiratory complexes. To measure the effect of itaconate on complex II/SDH activity, we permeabilized cells in the presence of rotenone (to eliminate the contribution of complex I), ADP, and succinate as substrate. Measurement of oxygen consumption rate (OCR) showed an immediate decrease in OCR following injection of either itaconate or malonate, a known SDH inhibitor used as a positive control. Addition of oligomycin did not cause a further reduction in OCR ([Figure 2A](#fig2){ref-type="fig"}). These data suggest that itaconate, like malonate, is indeed an SDH inhibitor. When cells were permeabilized in media containing only the complex I substrates pyruvate/malate, injection of itaconate caused a smaller decrease in OCR relative to that seen during complex II-dependent respiration. This reduction was again similar to what was observed with malonate (complex II inhibitor). Injection of oligomycin resulted in a significant drop in OCR. These results are consistent with itaconate mediating its inhibitory effects on respiration via complex II ([Figure 2B](#fig2){ref-type="fig"}).

![Itaconate decreases oxygen consumption rate via inhibition of complex II, succinate dehydrogenase (SDH).\
(**A**) We measured oxygen consumption rate (OCR) in permeabilized BMDMs (using XF plasma membrane permeabilizer) in the presence of ETC complex II substrate (succinate, 10 mM) and complex I inhibitor (rotenone, 2 mM), followed by injections of 1) media (control, *n* = 6), itaconate (10 mM, *n* = 6) or malonate (10 mM, *n* = 6), a known complex II inhibitor, 2) oligomycin (2 mM), an ATP synthase inhibitor, and 3) Antimycin A (2 mM), a complex III inhibitor. Both itaconate and malonate significantly decreased OCR. (**B**) We measured OCR in permeabilized BMDMs in the presence of ETC complex I substrates (pyruvate, 10 mM and malate, 0.5 mM) followed by injections of 1) itaconate or malonate, 2) oligomycin, or 3) rotenone and antimycin A (R/A) (*n* = 6). (**C**) We performed a mitochondrial stress test to measure OCR and ECAR in BMDMs treated with 4-octyl itaconate (OI) (0.25 mM) or vehicle control (*n* = 8). OI acutely decreased both (**D**) basal OCR and (**E**) maximal OCR measured at third time point after FCCP. Significance was determined using two-tailed unpaired student's t-test, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig2){#fig2}

Because there are no known mechanisms of transporting itaconate into the cell, studies have used different forms of itaconate that are cell membrane-permeable to examine the role of itaconate in vitro. 4-octyl itaconate (OI) has been shown to cross the plasma membrane and increase intracellular concentrations of itaconate ([@bib15]). We thus measured OCR in intact cells in the presence or absence of OI (0.25 mM, a dose shown by Mills et al to reduce LPS-induced inflammation \[[@bib15]\]). OI injection caused a small reduction in basal OCR, while basal ECAR increased slightly, which is likely as a compensatory response to reduction in OCR ([Figure 2C and D](#fig2){ref-type="fig"}). Oligomycin then decreased the OCR of both groups to the same level consistent with OI-induced reduction in coupled respiration. Maximal OCR determined following FCCP, an uncoupler, was lower in OI-treated BMDMs compared to control BMDMs ([Figure 2E](#fig2){ref-type="fig"}). Together, these results suggest that itaconate is sufficient to reduce mitochondrial OCR via inhibition of complex II/SDH.

PM causes time-dependent effects on mitochondrial oxygen consumption: An initial increase in OCR is followed by a late reduction in OCR {#s2-3}
---------------------------------------------------------------------------------------------------------------------------------------

Since itaconate inhibits mitochondrial respiration and ACOD1 is induced late following PM exposure, we sought to determine whether PM exposure exerts time-dependent changes in mitochondrial oxygen consumption rate in macrophages. We thus measured OCR in BMDMs following PM treatment at 1 hour and 24 hours, when ACOD1 expression is undetectable and present, respectively. As we have previously shown ([@bib20]), after 1 hour of exposure, cells treated with PM exhibited increased basal oxygen consumption rate compared with control BMDMs ([Figure 3A](#fig3){ref-type="fig"}). Consistent with a role of glycolysis in promoting inflammation, ECAR was also induced by PM exposure after 1 hour. Interestingly, after 24 hours of PM treatment, ECAR levels remained elevated; however, both basal and maximal OCR were decreased relative to control-treated cells. ([Figure 3B](#fig3){ref-type="fig"}). This decrease in OCR following 24 hours of PM treatment was similar to the decrease in OCR after itaconate treatment ([Figure 2C](#fig2){ref-type="fig"}) suggesting that ACOD1 induction and itaconate production are important regulators of macrophage metabolism following PM treatment.

![The effect of PM on mitochondrial oxygen consumption is time dependent.\
(**A**) We performed a mitochondrial stress test to measure OCR and ECAR in BMDMs at (**A**) 1 hour or (**B**) 24 hours following treatment with PM (20 μg/cm^2^) or control vehicle control. Oligomycin (ATP synthase inhibitor), FCCP (uncoupler), and rotenone/antimycin A (R/A) (complex I/III inhibitors) were injected sequentially. Basal OCR was acutely increased at 1 hour, which is before the induction of ACOD1 protein and production of itaconate. In contrast, both basal and maximal OCR decreased at 24 hours after PM treatment, when ACOD1 protein and itaconate levels are high (*n* = 8). ECAR was increased with PM at both timepoints. Significance was determined using two-tailed unpaired student's t-test, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig3){#fig3}

Endogenous itaconate production is required for PM-induced reduction in mitochondrial respiration and metabolic reprogramming in macrophages {#s2-4}
--------------------------------------------------------------------------------------------------------------------------------------------

We next sought to determine whether PM-induced ACOD1 expression and endogenous itaconate production is required for PM-induced changes in mitochondrial metabolism at 24 hours. In order to answer this question, we used BMDMs from *Acod1*^-/-^ mice, which lack the ability to produce itaconate. We first measured TCA cycle intermediates in WT and *Acod1*^-/-^ BMDMs at 24 hours following treatment with PM or vehicle. PM-induced production of itaconate was detectable only in WT but not in *Acod1*^-/-^ BMDMs, confirming that ACOD1 is required for itaconate production ([Figure 4A,B](#fig4){ref-type="fig"}). Consistent with the role of itaconate as an inhibitor of SDH, succinate accumulated in WT BMDMs, but not *Acod1*^-/-^ cells following PM treatment ([Figure 4A,C](#fig4){ref-type="fig"}). This finding provides further support for endogenously-produced itaconate inhibiting SDH and leading to accumulation of succinate, as SDH catalyzes the oxidation of succinate to fumarate. In contrast, *Acod1^-/-^* BMDMs had higher levels of TCA metabolites downstream of succinate (fumarate, malate) ([Figure 4A](#fig4){ref-type="fig"}), consistent with the idea that due to the absence of itaconate in these cells, SDH and consequently the oxidation of succinate to fumarate are not inhibited. These results are consistent with previous reports using LPS as a stimulus ([@bib12]). Overall, our metabolomics data suggest that PM causes a break in the TCA cycle that is Acod1 dependent.

![Acod1 and endogenous itaconate production is required for PM-reduced mitochondrial OCR via inhibition of SDH.\
(**A**) Heatmap of intracellular levels of TCA cycle metabolites and itaconate at 24 hours following treatment with PM. (**B--C**) Intracellular concentrations of (**B**) itaconate and (**C**) succinate in WT and *Acod1*^-/-^ cells with (*n* = 6) and without (*n* = 4) PM; itaconate is not detectable in *Acod1*^-/-^ cells, while succinate does not accumulate in *Acod1*^-/-^ cells. (**D**) Mitochondrial stress test of WT and *Acod1*^-/-^ BMDMs after 24 hours of PM treatment. OCR was normalized to baseline OCR in WT control BMDMs (untreated). Maximal OCR levels are only decreased in WT cells, and not *Acod1*^-/-^ cells following PM. Significance was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig4){#fig4}

To determine whether PM-induced ACOD1 expression and production of itaconate are required for the reduction of OCR at 24 hours following PM, we performed a mitochondrial stress test in WT and *Acod1*^-/-^ BMDMs. While WT BMDMs exhibited significantly reduced OCR following PM, *Acod1*^-/-^ cells treated with PM for 24 hours did not show any reduction in OCR compared to control treatment ([Figure 4D](#fig4){ref-type="fig"}). Collectively, these results suggest that endogenously-produced itaconate is required for PM-induced reduction in OCR.

While a recent study showed that nitric oxide production as a result of LPS exposure can modulate metabolic reprogramming and affect oxidative phosphorylation in macrophages ([@bib1]), we found that inducible nitric oxide synthase (iNOS) protein was produced only in BMDMs stimulated with LPS. PM did not induce iNOS expression in either wild-type or *Acod1*^-/-^ BMDMs ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Thus, nitric oxide production is likely to be minimal with PM as a stimulus, and would not play a large role in the regulation of oxidative phosphorylation following PM.

Exogenous, but not endogenous itaconate attenuates the PM-induced inflammatory response in macrophages {#s2-5}
------------------------------------------------------------------------------------------------------

We have previously shown that PM induces an inflammatory response in macrophages, including the release of proinflammatory cytokines such as IL-6 and TNFα ([@bib17]; [@bib3]). Since the expression of ACOD1 was time-dependent, we first sought to determine whether the effect of PM on cytokine expression was also time-dependent. We thus treated BMDMs with PM for 4, 8 or 24 hours and then analyzed the pro-inflammatory cytokine mRNA expression. We found that the mRNA expression of *Il6, Tnfa* and *Il1b* increased at 4 and 8 hours, and then decreased at 24 hours suggesting that PM-induced expression of cytokines is time-dependent similar to the expression of ACOD1 ([Figure 5A](#fig5){ref-type="fig"}).

![Exogenous but not endogenous itaconate decreases PM-induced inflammation.\
(**A**) We treated WT BMDMs with PM for 4, 8 or 24 hours and measured mRNA expression of *Tnfa, Il6* and *Il1b* by qPCR (*n* = 3). (**B**) We pretreated WT BMDMs with OI or vehicle control (DMSO) for 2 hours before we treated them with PM or vehicle control for 4 hours. We then measured mRNA expression of *Tnfa, Il6* and *Il1b* (qPCR). (**C, D**) We treated WT and *Acod1^-/-^* BMDMs with PM or ve and measured (**C**) mRNA expression of *Tnfa, Il6* and *Il1b* (qPCR). and (**D**) protein levels of IL-6 and TNFα in media (ELISA). IL-1β protein was not detectable. (**E, F**) We treated WT and *Acod1^-/-^* BMDMs with LPS (100 ng/ml) or PBS (control) and measured (**E**) mRNA expression of *Tnfa, Il6* and *Il1b* (qPCR). and (**F**) protein levels of IL-6, TNFα, and IL-1β in media (ELISA, *n* = 4). Significance was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig5){#fig5}

Since the reduction in inflammatory cytokine mRNA coincided with the induction of ACOD1 and itaconate production, we hypothesized that itaconate may play a role in the reduction in cytokine expression observed at 24 hours. To test this hypothesis, we first evaluated the effect of exogenous itaconate on the early PM-induced inflammatory response. We pre-treated BMDMs with OI for 2 hours before treating with PM for 4 hours and measured mRNA expression of pro-inflammatory cytokines by qPCR. Pretreatment with OI attenuated the PM-induced mRNA expression of *Tnfa*, *Il6* and *Il1b*, suggesting that accumulation of itaconate with the induction of ACOD1 may be responsible for reduced cytokine mRNA expression at 24 hours following PM treatment ([Figure 5B](#fig5){ref-type="fig"}).

To determine whether absence of itaconate accumulation would exaggerate PM-induced inflammation at later timepoints, we measured cytokine mRNA and protein level in both wild-type and *Acod1^-/-^* BMDMs 24 hours after exposure to PM. Interestingly, loss of itaconate accumulation did not result in increased mRNA expression of *Il6, Tnfa* or *Il1b* or protein level in media in *Acod1^-/-^* BMDMs ([Figure 5C,D](#fig5){ref-type="fig"}). While loss of Acod1/itaconate did not affect PM-induced IL-6 protein levels, there was a reduction in TNFα protein level in media ([Figure 5D](#fig5){ref-type="fig"}). Overall, these results suggest that endogenous itaconate does not attenuate the PM-induced inflammatory response.

This was a surprising finding as Acod1/itaconate deficiency has been shown to augment inflammatory cytokine expression in response to LPS ([@bib12]). To ensure that our findings were not the result of experimental differences other than stimulus, we treated wild-type and *Acod1^-/-^* BMDMs with LPS for 24 hours and measured *Il6, Tnfa* or *Il1b* mRNA expression. In contrast with PM treatment, *Acod1^-/-^* cells exhibited augmented *IL6* and *Il1b* mRNA expression after LPS treatment ([Figure 5E](#fig5){ref-type="fig"}), consistent with previously published results ([@bib12]). There was no effect of *Acod1* deletion on LPS-induced *Tnfa* expression ([Figure 5E](#fig5){ref-type="fig"}), also consistent with previous findings ([@bib12]). The loss of Acod1/itaconate also resulted in increased IL-6 and IL-1β protein level in media ([Figure 5F](#fig5){ref-type="fig"}). These findings suggest that the effect of itaconate on inflammation is stimulus-dependent. Importantly, these results also suggest that the effect of endogenously-produced itaconate on inflammation is different than that of exogenously-applied itaconate.

Differential effects of endogenous versus exogenous itaconate on the PM-induced transcriptomic response {#s2-6}
-------------------------------------------------------------------------------------------------------

To better understand the role of endogenous and exogenously-applied itaconate on PM-induced response in macrophages, we performed RNA-sequencing in *Acod1^-/-^* and WT BMDMs exposed to PM ([Figure 6A](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). We found only 51 DEGs between *Acod1^-/-^* and WT BMDMs following PM ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). Both inflammatory genes, including *Il1b* and *Tnfa*, and NRF2 target genes, including *Nqo1* and *Gclm*, were not significantly different between *Acod1^-/-^* and WT BMDMs. Next, to determine the effect of exogenous itaconate on PM-induced gene expression, we performed RNA-sequencing in WT BMDMs exposed to PM following 2 hours of pretreatment with vehicle or OI. Transcriptomic analysis showed 1,030 DEGs between groups with and without OI ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}). OI pretreatment significantly downregulated inflammatory gene expression in PM-treated BMDMs and upregulated NRF2 target genes. The effect of OI on these genes was not significantly different between WT and *Acod1^-/-^cells.* These results suggest that the effect of exogenous itaconate on the PM-induced transcriptomic response is markedly different from the effect of endogenous itaconate ([Figure 6A](#fig6){ref-type="fig"}).

![Endogenous and exogenous Itaconate have different effects on transcriptomic changes in response to PM.\
(**A**) PCA plot showing top 500 of 10,250 low expression removed gene features in WT or *Acod1*^-/-^BMDMs treated with PM and/or OI for 24 hours. (**B--C**) Volcano plots showing differentially expressed genes (DEGs) in (**B**) PM-treated *Acod1*^-/-^ BMDMs compared with PM-treated WT BMDMs (51 DEGs), and (**C**) OI and PM-treated WT BMDMs compared with only PM-treated WT BMDMs (1,030 DEGs). DEGs were identified using DESeq2 at FC \> 2 and FDR adjusted p-value of p\<0.05. Dark gray points represent significantly different genes; light gray points represent not significantly different genes. Inflammatory genes (orange) and NRF2 target genes (turquoise) were not significantly different between WT and *Acod1*^-/-^ BMDMs, while OI-pretreated BMDMs significantly expressed fewer inflammatory genes and more NRF2 target genes compared to BMDMs without OI pretreatment.\
Figure 6---source data 1.Table of gene feature counts for all samples as generated using featureCounts.\
Figure 6---source data 2.Differential expression analysis results of PM treated *Acod1^-/-^* BMDMs compared with PM treated WT BMDMs.\
Figure 6---source data 3.Differential expression analysis results of OI and PM treated BMDMs compared with only PM treated BMDMs.](elife-54877-fig6){#fig6}

Endogenous itaconate production is not required for PM- or LPS-induced NRF2 expression {#s2-7}
--------------------------------------------------------------------------------------

Recent studies suggest that itaconate exerts its inhibitory effects on LPS-induced inflammation via activation of NRF2, a transcriptional factor that plays a key role in antioxidant defense ([@bib15]). Both PM and LPS induce mitochondrial production of reactive oxygen species which promote inflammatory gene expression ([@bib10]; [@bib19]); however, PM contains a mixture of metals and other compounds which have their own redox-modulating properties ([@bib11]). We thus hypothesized that differential effects of PM and LPS on NRF2 activation may explain the lack of effect of endogenous itaconate on inflammation in PM-treated *Acod1^-/-^* BMDMs. We found that PM upregulated NRF2 and its target genes (*Nqo1, Gclm, Hmox1*) equally in WT and *Acod1*^-/-^ BMDM ([Figure 7A,B](#fig7){ref-type="fig"}). These results suggested that itaconate-independent activation of NRF2 might explain the fact that no augmented inflammatory gene expression was observed in *Acod1^-/-^* cells after PM exposure.

![Acod1 and endogenous Itaconate production is not required for PM and LPS-induced activation of NRF2 pathway.\
(**A, B**) We treated WT and *Acod1*^-/-^ BMDMs with PM for 24 hours and measured (**A**) protein expression of NRF2 (Western blot) and (**B**) mRNA expression of NRF2 target genes *Nqo1, Hmox1* and *Gclm* (qPCR). NRF2 protein and target genes are unchanged between WT and *Acod1*^-/-^ (**C, D**) We treated WT and *Acod1*^-/-^ BMDMs with LPS (100 ng/ml) for 24 hours and measured (**C**) protein expression of NRF2 (Western blot) and (**D**) mRNA expression of NRF2 target genes *Nqo1, Hmox1* and *Gclm* (qPCR). NRF2 protein is not different between WT and *Acod1*^-/-^ cells. (**E**) We treated WT BMDMs with LPS for 4, 8, and 24 hours and measured protein expression of NRF2 and ACOD1 (Western blot) over time. Dimethyl fumarate (DMF, 0.1 mM) was used as a positive control for NRF2 expression. The expression of NRF2 precedes ACOD1 and the peak expression of NRF2 occurs before the peak expression of ACOD1. Significance of qPCR data was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig7){#fig7}

As our experiments in *Acod1^-/-^* BMDMs showed that Acod1 is not required for PM-induced NRF2 activation, we sought to determine whether endogenous itaconate production is required for LPS-induced NRF2 activation. Surprisingly, we found that similar to PM-induced NRF2 activation, Acod1 expression was not required for LPS-mediated induction of NRF2 protein or target gene expression ([Figure 7C,D](#fig7){ref-type="fig"}). NRF2 protein levels were similarly upregulated in both LPS-treated WT and *Acod1^-/-^* cells ([Figure 7C](#fig7){ref-type="fig"}). While *Gclm* expression was slightly reduced in *Acod1^-/-^* cells, *Hmox1* induction was not affected by *Acod1* deficiency and *Nqo1* was more highly induced by LPS in *Acod1^-/-^* cells ([Figure 7D](#fig7){ref-type="fig"}).

Furthermore, we found that NRF2 induction after LPS treatment occurs prior to Acod1 induction ([Figure 7E](#fig7){ref-type="fig"}). Treatment with LPS induced a time-dependent expression of ACOD1 and NRF2. Interestingly, expression of NRF2 occurred at an earlier time point compared to ACOD1 (4 hours vs. 8 hours). Maximal expression of NRF2 also preceded the maximal expression of ACOD1 (8 hours vs 24 hours). Taken together, our results suggest that although NRF2 activation has been proposed to be the mechanism by which itaconate exerts its inflammatory effect, NRF2 induction occurs prior to ACOD1, and furthermore, ACOD1 is not required for NRF2 activation downstream of either PM or LPS.

NRF2 is not required for the anti-inflammatory effects of exogenous itaconate {#s2-8}
-----------------------------------------------------------------------------

To date, the majority of studies investigating the role of Acod1 and itaconate on inflammation, including those linking NRF2 to the mechanisms by which itaconate may regulate inflammation, have largely focused on the effects of exogenously-applied cell membrane-permeable forms of itaconate (e.g., dimethyl itaconate and OI) ([@bib12]; [@bib2]; [@bib15]; [@bib25]). NRF2 has been suggested to regulate the effect of OI on IL-1β expression; however, as we saw that OI reduced PM and LPS-induced expression of other cytokines, including TNFα, the expression of which is not regulated by endogenous itaconate, we examined whether the effect of OI on these cytokines was regulated by NRF2. We found that, consistent with previous findings ([@bib15]), OI treatment was sufficient to induce NRF2 protein and expression of NRF2 target genes (*Nqo1*, *Gclm*, and *Hmox1*) ([Figure 8A,B](#fig8){ref-type="fig"}). OI induced NRF2 protein expression to a similar extent as PM, and the combination of OI and PM caused a further increase in NRF2 protein levels and expression of its target gene, *Nqo1* ([Figure 8A,B](#fig8){ref-type="fig"}).

![NRF2 is not required for the anti-inflammatory effects of exogenous itaconate (OI) on PM-induced inflammatory response.\
(**A**) Western blot showing upregulation of NRF2 protein following 2 hours of OI pretreatment (0.25 mM) followed by 4 hours of PM (20 µg/cm^2^) treatment. The combination of OI and PM further increased NRF2 activation. (**B**) qPCR of NRF2 target genes (*Nqo1*, *Gclm*, and *Hmox1)* in WT BMDMs treated with PM for 4 hours, with or without OI pretreatment (0.25 mM, for 2 hours). (**C**) BMDMs transfected with scramble control siRNA or *Nfe2l2* siRNA (\#1), Western blot analysis of control siRNA and *Nfe2l2* siRNA (\#1)-transfected BMDMs following 4 hours of PM treatment to induce NRF2 protein. (**D**) qPCR of pro-inflammatory cytokine genes (*Tnfa*, *Il6* and *Il1b*) in *Nfe2l2* siRNA-transfected BMDMs treated with OI (2 hours of pretreatment) and PM (4 hours). Significance of qPCR was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig8){#fig8}

To determine whether NRF2 is required for the OI-mediated attenuation of inflammatory cytokine expression, we transfected BMDMs with two independent siRNAs targeting *Nfe2l2*, or a non-targeting control. NRF2 protein was confirmed to be eliminated by Western blot analysis, as *Nfe2l2* siRNA-transfected cells did not upregulate NRF2 protein following 4 hours of PM treatment ([Figure 8C](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

Despite the loss of NRF2, we found that OI still exhibited its anti-inflammatory effects on PM-induced inflammation. OI attenuated PM-induced proinflammatory cytokine (*Tnfa*, *Il6*, *Il1b*) expression in both control and NRF2 knockdown cells ([Figure 8D](#fig8){ref-type="fig"}). These data suggest that NRF2 is not required for exogenous itaconate to attenuate PM-induced inflammation and are in contrast to recent results suggesting that OI exerts its anti-inflammatory effect on LPS-induced inflammation by upregulating NRF2 ([@bib15]).

Because of the differences between PM and LPS, we then looked at the effect of OI on LPS-induced inflammation. While OI similarly decreased LPS-induced inflammation ([Figure 9A](#fig9){ref-type="fig"}), in contrast to PM treatment, LPS alone did not induce significant NRF2 target gene activation after 4 hours. No additional effect was seen on NRF2 target gene expression with the combination of LPS and OI ([Figure 9B](#fig9){ref-type="fig"}). Furthermore, consistent with our findings with PM, OI reduced inflammatory gene expression in response to LPS independent of NRF2 induction ([Figure 9C](#fig9){ref-type="fig"}, [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). Taken together, our results suggest that although NRF2 is induced by OI, this activation is not required for the anti-inflammatory effect of exogenous itaconate.

![NRF2 is not required for the anti-inflammatory response of exogenous itaconate (OI) on LPS-induced inflammatory response.\
(**A--B**) qPCR of (**A**) proinflammatory cytokine (*Tnfa*, *Il6* and *Il1b*) genes and (**B**) NRF2 target genes (*Nqo1*, *Gclm*, and *Hmox1)* in WT BMDMs treated with LPS (100 ng/ml, 4 hours), with or without OI pretreatment (0.25 mM, 2 hours). (**C**) qPCR of pro-inflammatory cytokine genes (*Tnfa*, *Il6* and *Il1b*) in control or *Nfe2l2* siRNA (\#1)-transfected BMDMs treated with LPS for 4 hours, with or without OI pretreatment (0.25 mM, 2 hours). Significance of qPCR was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons, *n* = 3; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig9){#fig9}

Itaconate does not modulate PM-induced inflammation or NRF2 response in vivo {#s2-9}
----------------------------------------------------------------------------

Lungs are the primary site of entry for PM, and we have previously demonstrated that alveolar macrophages (AMs) are metabolically distinct from BMDMs ([@bib24]). We thus sought to determine whether the role of itaconate in AMs is similar to what we observed in BMDMs. We first isolated alveolar macrophages from WT and *Acod1*^-/-^ mice and then treated them with PM as we did in BMDMs ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). As expected, there was no *Acod1* expression in *Acod1*^-/-^alveolar macrophages and treatment with PM induced a significant increase in the expression of *Acod1* mRNA in WT alveolar macrophages ([Figure 10---figure supplement 1A](#fig10s1){ref-type="fig"}). PM increased the expression of inflammatory cytokine genes (*Il6*, *Tnfa*, and *Il1b*) as well as IL-6 and TNFα protein levels in media both in WT and *Acod1*^-/-^alveolar macrophages ([Figure 10---figure supplement 1B,C](#fig10s1){ref-type="fig"}). There was no difference in cytokine mRNA or protein expression between WT and *Acod1*^-/-^alveolar macrophages. As we observed in BMDMs, PM caused similar increases in the expression of NRF2 target genes in WT and *Acod1*^-/-^alveolar macrophages ([Figure 10---figure supplement 1D](#fig10s1){ref-type="fig"}).

We next investigated whether itaconate plays a role in inflammation in an in vivo model. We intratracheally instilled either PBS or PM (in PBS) into the lungs of WT and *Acod1*^-/-^ mice as we previously described ([@bib16]; [@bib17]). Twenty-four hours after instillation, we obtained bronchoalveolar lavage (BAL) fluid to measure cytokine levels as well as to isolate AMs for gene expression analysis. AM expression of *Acod1* was significantly induced by PM in WT mice only ([Figure 10A](#fig10){ref-type="fig"}). Inflammatory cytokine genes (*Il6*, *Tnfa*, and *Il1b*) were significantly induced by PM in AMs from both WT and *Acod1*^-/-^ mice. There was no difference in levels of inflammatory cytokine genes between the WT and *Acod1*^-/-^ groups ([Figure 10B](#fig10){ref-type="fig"}). Analysis of cytokine levels in the BAL fluid by ELISA showed similar increases in IL-6 and TNFα following PM treatment, with no differences between WT and *Acod1*^-/-^ mice ([Figure 10C](#fig10){ref-type="fig"}). Collectively, these data suggest that itaconate does not play a role in PM-induced inflammation in vitro or in vivo.

![Acod1 and Itaconate are not required for PM-induced inflammation in an in vivo model of PM exposure.\
WT and *Acod1^-/^*^-^mice were treated intratracheally with PM (100 μg) or PBS and 24 hours later, bronchoalveolar lavage (BAL) fluid was collected to obtain alveolar macrophages and cytokine levels in fluid. (**A**) *Acod1* gene expression is induced in alveolar macrophages by in vivo PM treatment in WT mice as measured by qPCR. (**B**) Inflammatory genes (*Il6, Tnfa, Il1b*) as measured by qPCR were equally upregulated by PM treatment in vivo in both WT and *Acod1*^-/-^ mice. (**C**) Cytokine levels of IL-6 and TNFα in BAL fluid as measured by ELISA; IL-6 and TNFα levels increase equally with PM treatment in both WT and *Acod1*^-/-^ mice. (**D**) NRF2 target genes (*Nqo1*, *Gclm*, *Hmox1*) were upregulated with PM treatment as measured by qPCR, with no difference between WT and *Acod1*^-/-^ mice. Significance was analyzed with one-way ANOVA corrected with Bonferroni's post hoc test for multiple comparisons, *n =* 6; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-54877-fig10){#fig10}

Discussion {#s3}
==========

Exposure to PM air pollution is associated with significant morbidity and mortality ([@bib9]). Air pollution exposure is one of the top preventable causes of death in the world ([@bib13]). It is estimated that exposure to air pollution causes 4.2 million premature deaths worldwide every year according to the World Health Organization ([@bib9]; [@bib23]). Since limiting exposure to PM cannot be achieved immediately, a better understanding of the mechanisms by which PM causes morbidity and mortality is required in order to combat the effects of air pollution on public health.

As lungs are the entry site for PM, it is not surprising that lung inflammation plays an important role in PM-induced adverse health effects, which are predominantly cardiopulmonary diseases. We have previously reported that macrophages, and in particular, their production of IL-6, are required for the PM-induced lung inflammation and resultant acute thrombotic cardiovascular events ([@bib17]; [@bib3]; [@bib20]). However, the mechanisms regulating PM-induced inflammation in the lung are not completely understood.

In this study, using an unbiased approach with RNA-seq, we first discovered *Acod1* as the gene most induced by PM in macrophages. In a time-dependent fashion, PM induced the mRNA and protein expression of ACOD1, which was not evident at earlier time points (4, 8 hours) but was detected at 24 hours. Confirming a functional role, PM-induced expression of ACOD1 led to production of itaconate in our metabolomics measurements.

Assessment of the effect of PM on mitochondrial function showed that PM has a time-dependent effect on mitochondrial respiration. While PM increased mitochondrial OCR at 1 hour, it reduced OCR at 24 hours. Similarities in the time dependency between the effects of PM on ACOD1/itaconate and mitochondrial respiration led us to explore whether itaconate is responsible for the late reduction of OCR following PM exposure. Using *Acod1^-/-^* macrophages, we found that itaconate is required for the PM-induced reduction in mitochondrial OCR at 24 hours. Consistent with a role of itaconate as an inhibitor of succinate dehydrogenase, we found that *Acod1^-/-^* BMDMs lack succinate accumulation following PM treatment. This finding is in agreement with findings by Cordes et al., which showed a loss of succinate accumulation in response to LPS stimulation in *Acod1^-/-^* macrophages ([@bib5]). Collectively, our data support a key role for Acod1 and itaconate in the metabolic reprogramming of macrophages in response to both LPS and PM stimulation.

Interestingly, although we found that endogenous itaconate production was an important regulator of mitochondrial metabolism and respiration in PM-treated macrophages, we were unable to find an effect of endogenous itaconate on PM-induced inflammation. This was in contrast to the effect of *Acod1* deletion on LPS-induced inflammation, in which IL-6 and IL-1β induction was augmented in the absence of endogenous itaconate production. Our results show a stimulus dependency for the effect of itaconate that has not been previously demonstrated. Thus, although PM and LPS both promote inflammatory cytokine expression and itaconate-dependent metabolic reprogramming, the effects of itaconate on inflammation differ between the two stimuli.

To enhance our understanding of the role of itaconate in the lungs with PM exposure, we used an in vivo model of PM exposure in WT and *Acod1*^-/-^ mice. Similar to our in vitro data, in vivo exposure of mice to PM shows that while *Acod1* is highly upregulated in the lung macrophages following PM exposure, the presence or lack of *Acod1* did not affect inflammation in the lung. Expression of IL-6 and TNFα were equally increased with PM exposure, regardless of ACOD1 expression status.

To date, the majority of studies investigating the role of Acod1 and itaconate on metabolism have largely focused on the effects of exogenously-applied cell membrane-permeable forms of itaconate (e.g., dimethyl itaconate and OI) ([@bib12]; [@bib2]; [@bib25]). Following the initial studies with dimethyl itaconate ([@bib12]; [@bib2]; [@bib25]), a more recent study questioned whether treatment with dimethyl itaconate actually increases intracellular levels of itaconate ([@bib7]). In response to this limitation of dimethyl itaconate, Mills and colleagues proposed the use of OI as a cell permeable form of itaconate and demonstrated that OI does increase intracellular levels of itaconate ([@bib15]). Our results showing that OI reduces PM-induced cytokine production are in agreement with Mills and colleagues suggesting that the exogenous cell membrane-permeable version of itaconate has anti-inflammatory effects. However, given the differing effects of endogenous itaconate production versus OI treatment on PM-treated macrophages, our results suggest additional cautions should be taken when extrapolating the effects of cell-permeable itaconate analogs to the effects of endogenously-produced itaconate. This is highlighted by the fact that while OI is sufficient to induce NRF2 activation in macrophages, Acod1 is not required for NRF2 activation in response to PM or LPS. It would be expected that if a major effect of endogenous itaconate production were NRF2 activation, this should have been absent in *Acod1^-/-^* BMDMs. This loss of function experiment was notably lacking in the previous report linking itaconate with NRF2. Our results suggest that location of itaconate plays a major role in regulating its downstream effects.

While our results agree with Mills et al that OI activates the NRF2 antioxidant pathway by upregulation of NRF2 protein and its target genes, we found that NRF2 was dispensable for the anti-inflammatory effects of OI. Mills et al assessed the anti-inflammatory effects of OI by Western blot for intracellular IL-1β. Our findings examining the expression of multiple cytokines at the mRNA level suggest that NRF2 does not play a major role in regulating the anti-inflammatory effect of OI.

In conclusion, we found that exposure of macrophages to PM induces a mitochondrial enzyme, ACOD1 and production of a mitochondrial metabolite, itaconate, which is required for PM-induced metabolic reprogramming. Although endogenous itaconate reprograms mitochondrial function in PM-treated macrophages, it does not have a major effect on PM-induced gene expression or inflammatory response in vitro or in vivo. Future work will be required to determine whether endogenous itaconate regulates other macrophage functions. Our finding that itaconate is secreted from macrophages suggests that important, unexplored effects of itaconate production may occur in non-macrophage cells. Our results also caution about the interpretation of results achieved using exogenous cell membrane-permeable forms of itaconate as they may not represent the effects of endogenously-produced itaconate. Further, our results suggest that our understanding of the role of NRF2 in the cellular response to itaconate is far from complete. While OI is sufficient to induce NRF2 activation in macrophages, endogenous itaconate production is not required for PM or LPS-mediated NRF2 activation.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                               Designation                                 Source or reference                                             Identifiers                                                                                Additional\
  (species) or resource                                                                                                                                                                                                                              information
  ------------------------------------------- ------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------ -----------------------
  Gene (*M. musculus*)                        Acod1                                                                                                       Aconitate decarboxylase 1; Irg1                                                            

  Strain, strain background (*M. musculus*)   C57BL/6NJ\                                  Jackson Laboratory                                              Stock No. 005304                                                                           Male (7--11 weeks)
                                              (WT)                                                                                                                                                                                                   

  Strain, strain background (*M. musculus*)   C57BL/6NJ-*Acod1^em1(IMPC)J^*/J\            Jackson Laboratory                                              Stock No. 029340, RRID:[IMSR_JAX:029340](https://scicrunch.org/resolver/IMSR_JAX:029340)   Male (7--11 weeks)
                                              (Acod1 KO)                                                                                                                                                                                             

  Transfected construct (*M. musculus*)       Non-targeting siRNA                         Dharmacon                                                       D-001810-01-05                                                                             

  Transfected construct (*M. musculus*)       *Nfe2l2* siRNA \#1                          Dharmacon                                                       J-040766-08-0002                                                                           

  Transfected construct (*M. musculus*)       *Nfe2l2* siRNA \#2                          Dharmacon                                                       J-040766-06-0002                                                                           

  Antibody                                    Anti-β-actin (mouse, monoclonal)            Sigma Aldrich                                                   Catalog \#: A5441, RRID:[AB_476744](https://scicrunch.org/resolver/AB_476744)              WB (1:10,000)

  Antibody                                    Anti-ACOD1 (rabbit, polyclonal)             Thermo Fisher Scientific                                        Catalog \#: PA5-49094, RRID:[AB_2634550](https://scicrunch.org/resolver/AB_2634550)        WB (1:500)

  Antibody                                    Anti-NRF2 (rabbit, monoclonal)              Abcam                                                           Catalog \#:\                                                                               WB (1:1000)
                                                                                                                                                          Ab62352, RRID:[AB_944418](https://scicrunch.org/resolver/AB_944418)                        

  Antibody                                    Anti-iNOS\                                  Cell Signaling Technology                                       Catalog \#:\                                                                               WB (1:1000)
                                              (rabbit, polyclonal)                                                                                        2982, RRID:[AB_1078202](https://scicrunch.org/resolver/AB_1078202)                         

  Antibody                                    Anti-rabbit IgG, HRP-linked Antibody        Cell Signaling Technology                                       Catalog \#: 7074, RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)             WB (1:2000)

  Antibody                                    Anti-mouse IgG, HRP-linked Antibody         Cell Signaling Technology                                       Catalog \#:\                                                                               WB (1:2000)
                                                                                                                                                          7076, RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)                           

  Sequence-based reagent                      RPL13a_F                                    This paper                                                      PCR Primers                                                                                GAGGTCGGGTGGAAGTACCA

  Sequence-based reagent                      RPL13a_R                                    This paper                                                      PCR Primers                                                                                TGCATCTTGGCCTTTTCCTT

  Sequence-based reagent                      Acod1_F                                     This paper                                                      PCR Primers                                                                                TTTGGGGTCGACCAGACTTC

  Sequence-based reagent                      Acod1_R                                     This paper                                                      PCR Primers                                                                                CCATGGAGTGAACAGCAACAC

  Sequence-based reagent                      Il6_F                                       This paper                                                      PCR Primers                                                                                TCCTCTCTGCAAGAGACTTCC

  Sequence-based reagent                      Il6_R                                       This paper                                                      PCR Primers                                                                                AGTCTCCTCTCCGGACTTGT

  Sequence-based reagent                      Tnfa_F                                      This paper                                                      PCR Primers                                                                                ATGGCCTCCCTCTCATCAGT

  Sequence-based reagent                      Tnfa_R                                      This paper                                                      PCR Primers                                                                                TGGTTTGCTACGACGTGGG

  Sequence-based reagent                      Il1b_F                                      This paper                                                      PCR Primers                                                                                GCCACCTTTTGACAGTGATGA

  Sequence-based reagent                      Il1b_R                                      This paper                                                      PCR Primers                                                                                GACAGCCCAGGTCAAAGGTT

  Sequence-based reagent                      Nqo1_F                                      This paper                                                      PCR Primers                                                                                GGTAGCGGCTCCATGTACTC

  Sequence-based reagent                      Nqo1_R                                      This paper                                                      PCR Primers                                                                                CGCAGGATGCCACTCTGAAT

  Sequence-based reagent                      Gclm_F                                      This paper                                                      PCR Primers                                                                                AGTTGACATGGCATGCTCCG

  Sequence-based reagent                      Gclm_R                                      This paper                                                      PCR Primers                                                                                CCATCTTCAATCGGAGGCGA

  Sequence-based reagent                      Hmox1_F                                     This paper                                                      PCR Primers                                                                                GAGCAGAACCAGCCTGAACT

  Sequence-based reagent                      Hmox1_R                                     This paper                                                      PCR Primers                                                                                AAATCCTGGGGCATGCTGTC

  Sequence-based reagent                      Nos2_F                                      This paper                                                      PCR Primers                                                                                TTCACAGCTCATCCGGTACG

  Sequence-based reagent                      Nos2_R                                      This paper                                                      PCR Primers                                                                                TCGATGCACAACTGGGTGAA

  Commercial assay or kit                     Direct-zol RNA Miniprep Kits                Zymo Research                                                   R2053                                                                                      

  Commercial assay or kit                     Mouse IL-6 DuoSet ELISA                     R and D Systems                                                 DY406                                                                                      

  Commercial assay or kit                     Mouse TNF-alpha DuoSet ELISA                R and D Systems                                                 DY410                                                                                      

  Commercial assay or kit                     Seahorse XFe24 FluxPak                      Agilent                                                         102340--100                                                                                

  Commercial assay or kit                     Seahorse XF Plasma Membrane Permeabilizer   Agilent                                                         102504--100                                                                                

  Commercial assay or kit                     Mouse Macrophage Nucleofector Kit           Lonza                                                           VPA-1009                                                                                   

  Chemical compound, drug                     4-Octyl Itaconate                           Sigma Aldrich                                                   SML2338                                                                                    

  Chemical compound, drug                     Itaconic Acid                               Sigma Aldrich                                                   I29204                                                                                     

  Chemical compound, drug                     Malonic Acid                                Sigma Aldrich                                                   M1296                                                                                      

  Chemical compound, drug                     Pyruvic Acid                                Sigma Aldrich                                                   107360                                                                                     

  Chemical compound, drug                     Malic Acid                                  Sigma Aldrich                                                   02288                                                                                      

  Chemical compound, drug                     Succinic Acid                               Sigma Aldrich                                                   S3674                                                                                      

  Chemical compound, drug                     Particulate Matter (PM)                     NIST                                                            Urban Dust - SRM 1649a                                                                     

  Chemical compound, drug                     Lipopolysaccharide                          Santa Cruz                                                      sc-3535                                                                                    

  Chemical compound, drug                     Oligomycin                                  Fisher Scientific                                               49-545-510MG                                                                               

  Chemical compound, drug                     FCCP                                        Sigma Aldrich                                                   C2920                                                                                      

  Chemical compound, drug                     Antimycin A                                 Sigma Aldrich                                                   A8674                                                                                      

  Chemical compound, drug                     Rotenone                                    Sigma Aldrich                                                   R8875                                                                                      

  Chemical compound, drug                     Recombinant Mouse M-CSF                     BioLegend                                                       576408                                                                                     

  Software, algorithm                         Prism 8                                     GraphPad                                                        RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                               

  Software, algorithm                         FastQC                                      Babraham Institute                                              RRID:[SCR_014583](https://scicrunch.org/resolver/SCR_014583)                               

  Software, algorithm                         STAR                                        PMID:[23104886](https://www.ncbi.nlm.nih.gov/pubmed/23104886)   RRID:[SCR_015899](https://scicrunch.org/resolver/SCR_015899)                               

  Software, algorithm                         Picard                                      Broad Institute                                                 RRID:[SCR_006525](https://scicrunch.org/resolver/SCR_006525)                               

  Software, algorithm                         RSeQC                                       PMID:[22743226](https://www.ncbi.nlm.nih.gov/pubmed/22743226)   RRID:[SCR_005275](https://scicrunch.org/resolver/SCR_005275)                               

  Software, algorithm                         FeatureCounts                               WEHI                                                            RRID:[SCR_012919](https://scicrunch.org/resolver/SCR_012919)                               

  Software, algorithm                         DESeq2                                      Bioconductor                                                    RRID:[SCR_015687](https://scicrunch.org/resolver/SCR_015687)                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell isolation and culture {#s4-1}
--------------------------

All animal experiments and procedures were performed according to the protocols approved by the Institutional Animal Care and Use Committee at the University of Chicago. We used primary murine cells (bone marrow-derived macrophages (BMDMs)), which we isolated as we have recently reported ([@bib24]). Hematopoietic cells were isolated from bone marrow of C57BL/6NJ (Stock No: 005304) and *Acod1^-/-^* (Stock No: 029340) (both from Jackson Laboratory) mice and cultured with M-CSF (20 µg/L, BioLegend, catalog number 576408) in vitro for 8--10 days to generate BMDMs. Tissue-resident alveolar macrophages were isolated by standard BAL fluid collection, as we have previously described ([@bib3]; [@bib20]), and cultured in media for 2 hr before treatment. For all experiments, cells were cultured in complete medium containing RPMI (Gibco, catalog number A10491), supplemented with 10% heat-inactivated FBS (Gemini, catalog number 100--106) and 1% penicillin-streptomycin (Gemini, 400--109).

Reagents were purchased from Sigma-Aldrich, including: 4-Octyl itaconate (catalog number SML2338), Itaconic Acid (catalog number I29204), Malonic Acid (M1296). Particulate matter (SRM 1649a, Urban Dust) was from National Institute of Standards Technology (NIST). Lipopolysaccharide was purchased from Santa Cruz (sc-3535). Full details of reagents used are included in the Key Resources Table.

Cell lysis and western blotting {#s4-2}
-------------------------------

Cells were scraped into RIPA buffer (Thermo-Scientific, catalog number 89900) with protease and phosphatase inhibitors (Thermo-Scientific, 1861284), sonicated for 10 s on a Fisher Scientific 100 model at speed setting 2. Samples were resolved by SDS-PAGE on 10% polyacrylamide gels and transferred to nitrocellulose (Bio-Rad, catalog number 1620167). Primary antibodies used were mouse anti-β-actin monoclonal antibody (Sigma, catalog number A5441; lot number 037K488; 1:10,000), ACOD1 polyclonal antibody (Invitrogen, catalog number PA5-49094, 1:500), NRF2 monoclonal antibody (Abcam, catalog number ab62352, 1:1000), iNOS Antibody (Cell Signaling Technology, catalog number 2982S, 1:1000). Secondary antibodies used were anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology, catalog number 7074S) and anti-mouse IgG HRP-linked antibody (Cell Signaling Technology, catalog number 7076S).

Quantitative PCR {#s4-3}
----------------

Total RNA was extracted with TRI Reagent (Zymo Research, R2050-1-200). RNA was then isolated using the Zymo Direct-zol RNA Miniprep Kit (Zymo Research, catalog number R2053) and reverse-transcribed using Bio-Rad iScript Reverse Transcription Supermix (Bio-Rad, catalog number 1708841) in a Bio-Rad C1000 Touch Thermal Cycler. Quantitative mRNA expression was determined by real-time qPCR using iTaq Universal SYBR Green Supermix (Bio-Rad, catalog number 172--5121).

qPCR primer sequences used are as follows:

1.  *Rpl13a* (control) (5'-GAGGTCGGGTGGAAGTACCA-3', 5'-TGCATCTTGGCCTTTTCCTT-3'),

2.  *Acod1* (5'-TTTGGGGTCGACCAGACTTC-3', 5'-CCATGGAGTGAACAGCAACAC-3'),

3.  *Il6* (5'-TCCTCTCTGCAAGAGACTTCC-3', 5'-AGTCTCCTCTCCGGACTTGT-3'),

4.  *Tnfa* (5'-ATGGCCTCCCTCTCATCAGT-3', 5'-TGGTTTGCTACGACGTGGG-3'),

5.  *Il1b* (5'-GCCACCTTTTGACAGTGATGA-3',5'-GACAGCCCAGGTCAAAGGTT-3'),

6.  *Nqo1* (5'-GGTAGCGGCTCCATGTACTC-3', 5'-CGCAGGATGCCACTCTGAAT-3'),

7.  *Gclm* (5'-AGTTGACATGGCATGCTCCG-3', 5'-CCATCTTCAATCGGAGGCGA-3'),

8.  *Hmox1* (5'-GAGCAGAACCAGCCTGAACT −3', 5'- AAATCCTGGGGCATGCTGTC-3'),

9.  *Nos2* (5'-TTCACAGCTCATCCGGTACG −3', 5'- TCGATGCACAACTGGGTGAA-3').

ELISA {#s4-4}
-----

Cells were treated in complete medium for 24 hours, and the media was collected. IL-6 and TNFα cytokine levels in the media were then measured with DuoSet ELISA kits (R and D systems, catalog number DY406 and DY410) according to manufacturer's protocol.

RNA sequencing {#s4-5}
--------------

RNA was isolated and submitted for sequencing (50 bp SE). Quality assessment of sequencing files was assessed with FastQC. Reads were mapped to the GRCm38 reference genome using STAR aligner ([@bib6]), and quality was assessed using Picard tools and RSeQC ([@bib22]). Genes were quantified using featureCounts, and low expression genes were removed at cpm = 1.5. Differentially expressed genes (DEGs) were identified using DESeq2 analysis at FC \> 2 and FDR adjusted p-value p\<0.05.

Metabolomics {#s4-6}
------------

BMDMs were plated at 3 × 10^6^ cells on 60 mm tissue culture plates for 2 hours, then treated with PM (20 μg/cm^2^) for 24 hours prior to metabolite extraction. Cells were washed with 5% mannitol solution and metabolites were extracted with 400 μl methanol. 275 μl internal standard was added, then the extracts were centrifuged at 2,300 × g for 5 min. The supernatant was transferred to pre-washed centrifugal filter units (HMT, Human Metabolome Technologies, Boston, MA) and centrifuged at 9,100 × g at 4°C for 2 hours. Centrifuged samples were sent to HMT for processing and analysis.

Extracellular itaconate measurement {#s4-7}
-----------------------------------

This measurement was performed by Mass spectrometry, Metabolomics and Proteomics Facility in Research Resources Center of University of Illinois at Chicago. All samples are analyzed by Waters ACQUITY UPLC BEH C18 Column, 130Å, 1.7 μm, 2.1 mm X 100 mm coupled to an Agilent 1260 UPLC system, which was operated at a flow rate of 500 uL/min. A linear gradient of 1--60% buffer B (100% MeOH) was applied. MS data were acquired by MRM scan (Negative ESI spray voltage 4.5kV, temperature 550 degrees, m/z range 50--300) monitoring signature product ions 129 \> 69 (Quantifier) and 129 \> 59 (Qualifier) transitions. The quantification was achieved using peak area of monitored transitions. All the samples were analyzed by triplicate.

siRNA knockdowns {#s4-8}
----------------

BMDMs (1 × 10^6^ cells) were transfected with siRNA (250 pmol) and Amaxa Mouse Macrophage Nucleofector Kit (Lonza, catalog number VPA-1009) using a Lonza Nucleofector 2b device (Lonza, \#AAB-1001) on the mouse macrophage (Y-001) setting. Cells were cultured for 2 days post transfection before treatment. Success of siRNA transfections were confirmed with western blots and qPCR. siRNAs were purchased from Dharmacon: D-001810-01-05 (non-targeting siRNA); J-040766-08-0002 (*Nfe2l2* \#1), J-040766-06-0002 (*Nfe2l2* \#2).

Seahorse analysis {#s4-9}
-----------------

The Seahorse XF^e^24 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA), was used to measure oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) as we have previously described ([@bib18]; [@bib8]; [@bib20]; [@bib24]). Macrophages were seeded at a density of 4 × 10^4^ per well on a Seahorse XF24 Cell Culture Microplate ([@bib24]).

Mitochondrial stress tests were performed according to manufacturer's protocol in XF DMEM base medium (Agilent 103334--100) containing Glutamine (2 mM), Sodium Pyruvate (1 mM), and Glucose (25 mM). Compounds of interest were injected, followed by sequential injections of Oligomycin (1.5 μM), FCCP (1.5 μM) and Antimycin A/Rotenone (1.25 μM).

Membrane permeabilization assays were performed in 1x MAS buffer containing mannitol (220 mM), sucrose (70 mM), monopotassium phosphate (10 mM), magnesium chloride (5 mM), HEPES (2 mM), EGTA (1 mM), with the addition of Seahorse XF Plasma Membrane Permeabilizer (Agilent, catalog number 102504--100) and Fatty Acid Free BSA (0.2%). Substrates and reagents used in permeabilization assays include succinate (10 mM), rotenone (2 mM), pyruvate (10 mM), malate (0.5 mM), ADP (4 mM), itaconate (10 mM), malonate (10 mM), oligomycin (2 mM), antimycin A (2 mM). All substrates and reagents were pH-adjusted to 7.2 prior to assay with 5M potassium hydroxide (KOH) solution. Permeabilization assays were performed with cycles of 0.5 min mix, 0.5 min wait, and 2 min measure intervals, as per manufacturer's protocol.

In vivo mouse studies {#s4-10}
---------------------

C57BL/6NJ and *Acod1*^-/-^ mice were treated via intratracheal instillation with only PBS or PM in PBS as we have previously described ([@bib16]; [@bib17]). PM was freshly diluted to a 2.5 mg/ml stock, and 2 doses of 20 μl PM stock was given intratracheally to each mouse, for a total of 100 μg in 40 μl PBS per mouse. For the PBS controls, 2 doses of 20 μl PBS were given intratracheally to each mouse. Following 24 hours of exposure, BAL fluid was obtained by flushing the lungs with 0.5 mM EDTA in ice cold PBS as we have previously described ([@bib3]; [@bib20]). The first wash of 500 μl was collected and centrifuged, where the supernatant was then used for ELISA studies. The cell pellet was combined with the cells obtained from the subsequent eight washes, and used for analysis of mRNA expression through qPCR analysis.

Statistical analysis {#s4-11}
--------------------

Data were analyzed using Prism 8 (GraphPad Software, Inc). All data are shown as mean ± standard error of the mean (SEM). Significance was determined by unpaired two-tailed Student's t test (for comparisons between two samples), or by one-way ANOVA using Bonferroni correction for multiple comparisons. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.
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**Acceptance summary:**

The metabolite itaconate has recently gained a lot of interest for its anti-inflammatory role in inflammatory macrophages. Here Mutlu and colleagues found that endogenous itaconate produced by the enzyme Acod1 does not influence inflammatory responses in macrophages exposed to particulate matter (PM) in vitro or in a mouse model of PM-induced lung inflammation, or to the microbial product LPS.
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Summary:

Particulate matter from air pollution is known to induce macrophage inflammation, and in this manuscript, Mutlu and colleagues investigated the role of ACOD1/itaconate. The authors found that macrophages exposed to PM upregulated Acod1 and production of itaconate. Such itaconate production contributed to the ability of PM to suppress oxidative metabolism via effects on Complex II, although it did not appear to affect inflammatory gene induction. The authors also found that endogenous and exogenous itaconate have different effects on the macrophage response to PM, which is of interest given the many recent studies that have explored the use of OI and dimethyl-itaconate (DI) as therapeutics. The authors also found that endogenous itaconate (via ACOD1) and exogenous itaconate do not regulate NRF2 to modulate anti-inflammatory effects, in macrophages stimulated with either PM or bacterial LPS.

Essential revisions:

1\) Although the objective of this study was to understand the mechanisms behind PM-induced lung inflammation, the authors relied exclusively on PM stimulation of BMDMs in vitro and did not see any effect of ACOD1-mediated itaconate production on inflammatory gene induction. To strengthen physiological relevance, the authors should use models of PM-induced lung inflammation and examine lung and alveolar macrophages for induction of ACOD1 and production of itaconate, and compare WT and Acod1 KO mice for lung inflammation to determine the role of itaconate (or if not possible, co-administration of OI in WT mice).

2\) The authors should provide more details in Materials and methods (e.g., concentration of itaconate used) so that readers can better understand what was done and to allow for experiments to be reproduced by the scientific community.
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> Essential revisions:
>
> 1\) Although the objective of this study was to understand the mechanisms behind PM-induced lung inflammation, the authors relied exclusively on PM stimulation of BMDMs in vitro and did not see any effect of ACOD1-mediated itaconate production on inflammatory gene induction. To strengthen physiological relevance, the authors should use models of PM-induced lung inflammation and examine lung and alveolar macrophages for induction of ACOD1 and production of itaconate, and compare WT and Acod1 KO mice for lung inflammation to determine the role of itaconate (or if not possible, co-administration of OI in WT mice).

We agree that an in vivo model would enhance the physiological relevance of this study. We treated WT and *Acod1^-/-^* mice with either PBS or PM intratracheally and similarly found that itaconate does not affect inflammatory gene or cytokine production. Details of this experiment can be found in Figure 10. Furthermore, we found that in tissue resident alveolar macrophages, loss of Acod1 did not affect PM-induced proinflammatory response or NRF2 activation (Figure 10---figure supplement 1).

> 2\) The authors should provide more details in Materials and methods (e.g., concentration of itaconate used) so that readers can better understand what was done and to allow for experiments to be reproduced by the scientific community.

As suggested, we have revised the Materials and methods to include specific details, including concentrations and treatment times, for more clarity.
